1. Atkinson M (2002) Patent protection for pharmaceuticals: a comparative study of the law in the United States and Canada. Pac Rim L Policy 11:184
2. Abbott FM (2002) The Doha Declaration on TRIPS agreement and public health: lighting a dark corner at the WTO. J Int Econ L 469–505
3. Abbott F (2004) The Doha Declaration on the TRIPS agreement and public health and the contradictory trend in bilateral and regional free trade agreements. Quaker United Nations Office Occasional Papers, vol 14, p 8. Available at http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1977300
4. Adamini S, Maarse H, Versluis E, Light DW (2009) Policy making on data exclusivity in the European Union: from industrial interests to legal realities. J Health Polit Policy L 34(6):989–992
5. Adamski J, Godman B, Ofierska-Sujkowska G, Osińska B, Herholz H, Wendykowska K, Laius O, Jan S, Sermet C, Zara C, Kalaba M, Garuolienè K, Haycox A, Garattini S, Gustafsson LL (2010) Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European Payers. BMC Health Serv Res 10(153):1. Available at http://www.biomedcentral.com/1472-6963/10/153